glp-1 and cancer treatment GLP-1s appear to cut risk. Researchers are asking why how : NPR GLP-1RA and thyroid cancer: New

many appear to be becoming harder to tempt

Its about the credibility of American medicine and the integrity of our markets

1 While primarily known for diabetes treatment, this effect can also indirectly influence appetite and cravings related to blood sugar fluctuations

Interventions for treating oral lichen planus

placebo preserved 5.5% additional weight loss at 88 weeks Typical taper window / 8 to 16 weeks of stepwise dose reduction before full stop Switching GLP-1s / direct substitution on the same injection day is generally well tolerated per clinical practice guidelines Long-term therapy indication / AACE guidelines classify obesity as a chronic disease requiring ongoing treatment Cardiovascular benefit / SELECT trial showed 20% MACE reduction with semaglutide 2.4 mg over 34.2 months Why stopping a GLP-1 abruptly almost always triggers weight regain Abrupt discontinuation of a GLP-1 receptor agonist removes a pharmacological brake on appetite, gastric emptying, and reward-pathway signaling all at once

GLP-1 is a proglucagon derived peptide